Cervical cancer screening.

por van Oortmarrsen, G. J., Habbema, J. D.
Publicado 1990

Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer.

por van Oortmarssen, G. J., Habbema, J. D.
Publicado 1991

Low risk of cervical cancer during a long period after negative screening in the Netherlands

por van den Akker-van Marle, M E, van Ballegooijen, M, Habbema, J D F
Publicado 2003

Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning

por van Dijk, M R, Steyerberg, E W, Stenning, S P, Dusseldorp, E, Habbema, J D F
Publicado 2004

Population Screening for Colorectal Cancer: Faeces, Endoscopes or X-Rays?

por Ramsoekh, D., van Leerdam, M. E., van Ballegooijen, M., Habbema, J. D. F., Kuipers, E. J.
Publicado 2007

Preventive Pap-smears: balancing costs, risks and benefits.

por van Ballegooijen, M., Habbema, J. D., van Oortmarssen, G. J., Koopmanschap, M. A., Lubbe, J. T., van Agt, H. M.
Publicado 1992

Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular c...

por Steyerberg, E. W., Keizer, H. J., Fosså, S. D., Sleijfer, D. T., Bajorin, D. F., Donohue, J. P., Habbema, J. D.
Publicado 1996

Non-progression of cervical intraepithelial neoplasia estimated from population-screening data.

por Bos, A. B., van Ballegooijen, M., van Oortmarssen, G. J., van Marle, M. E., Habbema, J. D., Lynge, E.
Publicado 1997

Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis.

por Steyerberg, E. W., Keizer, H. J., Zwartendijk, J., Van Rijk, G. L., Van Groeningen, C. J., Habbema, J. D., Stoter, G.
Publicado 1993

External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients

por Vergouwe, Y, Steyerberg, E W, de Wit, R, Roberts, J T, Keizer, H J, Collette, L, Stenning, S P, Habbema, J D F
Publicado 2003

Extended duration of the detectable stage by adding HPV test in cervical cancer screening

por van den Akker-van Marie, M E, van Ballegooijen, M, Rozendaal, L, Meijer, C J L M, Habbema, J D F
Publicado 2003

Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness.

por van Ballegooijen, M., van den Akker-van Marle, M. E., Warmerdam, P. G., Meijer, C. J., Walboomers, J. M., Habbema, J. D.
Publicado 1997

The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening

por de Kok, I M C M, Polder, J J, Habbema, J D F, Berkers, L-M, Meerding, W J, Rebolj, M, van Ballegooijen, M
Publicado 2009

Preferences for colorectal cancer screening strategies: a discrete choice experiment

por Hol, L, de Bekker-Grob, E W, van Dam, L, Donkers, B, Kuipers, E J, Habbema, J D F, Steyerberg, E W, van Leerdam, M E, Essink-Bot, M L
Publicado 2010

Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels

por Hol, L, Wilschut, J A, van Ballegooijen, M, van Vuuren, A J, van der Valk, H, Reijerink, J C I Y, van der Togt, A C M, Kuipers, E J, Habbema, J D F, van Leerdam, M E
Publicado 2009